Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders

Overview

The purpose of this study is to investigate the potential beneficial effects of a daily supplement of Resveratrol (1000mg/day) on physical ability and on muscle metabolism in patients with verified mitochondrial myopathy and patients with a verified fatty acid oxidation defect of VLCAD and CPTII deficiencies. Investigators hypothesize an improved muscle metabolism, mitochondrial function, fatty acid oxidation and thus improvement of physical ability.

Full Title of Study: “Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders: A Double-blind, Placebo-controlled, Cross Over Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: October 1, 2019

Detailed Description

Study design: double-blind, randomized, placebo-controlled, cross-over study.

To ensure enough participants, and due to the risk of a heterogeneous cohort, a cross-over design is chosen, where participants are their own controls. 10 patients with mitochondrial myopathy and 10 patients with fatty acid oxidation defects will be included. Eligible patients will be randomized using a 1:1 assignment ratio to receive placebo or RSV first. Each treatment will be administered orally twice daily for 8 weeks, followed by a 4 weeks wash-out, and afterwards a new 8-week treatment period.

During the 20-week trial period, subjects will visit the trial site on five occasions, for functional assessments (cycle ergometer testing), blood sampling and questionnaires.

Interventions

  • Dietary Supplement: Resveratrol
    • Resveratrol supplementation 1000 mg /day or placebo

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo
  • Experimental: Resveratrol
    • Over the counter supplement

Clinical Trial Outcome Measures

Primary Measures

  • Heart rate
    • Time Frame: 20 weeks
    • Decrease in heart rate during constant load cycling exercise.

Secondary Measures

  • Peak oxygen utilization
    • Time Frame: 20 weeks
    • VO^2max (ml/min)
  • Fatty acid oxidation
    • Time Frame: 20 weeks
    • Fatty acid oxidation will be assessed by stable isotope technique (only for fatty acid oxidation defect disease subgroup)
  • Perceived exertion
    • Time Frame: 20 weeks
    • Evaluation of perceived exertion (Borg score) during constant workload cycling
  • Fatigue Severity Scale score
    • Time Frame: 20 weeks
    • Evaluation of self-rated fatigue
  • SF-36 questionnaire
    • Time Frame: 20 weeks
    • Evaluation of self-rated daily function scores

Participating in This Clinical Trial

Inclusion Criteria

1. Patient is willing and able to provide written informed consent prior to participation.

2. Patient is ≥18 and ≤80 years of age at baseline.

3. Patients have genetically verified mitochondrial disorder or a fatty acid oxidation deficiency (VLCAD/CPTII).

4. Patient has a clinical presentation, signs or symptoms suggestive of myopathy (e.g., easy fatigability, exercise intolerance, muscle pain) in the opinion of the Investigator.

5. Patient is ambulatory.

Exclusion Criteria

1. Patient has any prior or current medical conditions that, in the judgment of the Investigator, would prevent the patient from safely participating in and/or completing all study requirements.

2. Patient has symptoms of mitochondrial myopathy due to known secondary mitochondrial dysfunction (e.g., drug-induced myopathy).

3. Patient does not have the cognitive capacity to understand/comprehend and complete all study assessments.

4. Pregnancy or breastfeeding

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rigshospitalet, Denmark
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nicoline Løkken, Medical Doctor – Rigshospitalet, Denmark
  • Overall Official(s)
    • John Vissing, professor, Study Director, Copenhangen Neuromuscular Center, Rigshospitalet, Denmark

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.